ABSTRACT

New personalized immunotherapies hold considerable promise among cancer communities and are touted by many as the future of oncology. Described as a way to enhance the body’s “natural defense” against cancer, they are made with antigens taken from patients’ own tumor tissue. However, they also set up significant dilemmas for patients who are learning what it is like to participate in an emerging tissue economy and the stakes of exclusion from it. Taking brain tumors as my ethnographic case, I chart the valuations and exchanges that constitute this tissue economy as well as the dilemmas and disparities faced by patients.

中文翻译：

---

新兴组织经济学：个性化免疫疗法和癌症治疗价值

摘要

新的个性化免疫疗法在癌症社区中具有相当大的前景，并被许多人吹捧为肿瘤学的未来。它们被描述为一种增强人体对癌症“自然防御”的方法，它们是用取自患者自身肿瘤组织的抗原制成的。然而，他们也为正在了解参与新兴组织经济的感觉以及被排除在外的风险的患者设置了重大困境。以脑肿瘤作为我的民族志案例，我绘制了构成这种组织经济的估值和交流，以及患者面临的困境和差异。